DR-TB Drug Combination has immense benefits: MSF Research
New research published today in The Lancet Infectious Diseases journal by the international medical humanitarian organisation Doctors Without Borders/Médecins Sans Frontières (MSF) provides strong evidence that a combination of two new drugs for tuberculosis (TB)—the world’s leading infectious disease killer—could be used to treat drug-resistant (DR-TB) forms of the disease. These findings encourage the wider use of…